Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the launches of Neurochem's Alzhemed and Myriad Genetics' Flurizan will be major factors in driving the market for the treatment of Alzheimer's disease to more than double to $4 billion by 2013.

According to the new Pharmacor study entitled Alzheimer's Disease, a dramatic change in market dynamics will begin half way through the study's 2003 to 2013 forecast period, as the first disease-modifying therapies-- including Alzhemed (NC-531) and Flurizan (R-flurbiprofen)--enter the market. These two therapies will account for more than 56% of Alzheimer's disease treatment sales in the United States, Western Europe, and Japan.

"Acetylcholinesterase inhibitors (AChEIs) will continue to dominate the Alzheimer's disease market until 2008, with the defining trend during this period being a shift in market share among competing AChEIs," said Michelle Grady, analyst at Decision Resources. "Eisai/Pfizer's Aricept (donepezil) will retain its leadership position, as Shire/Janssen's Reminyl (galantamine) and, to a lesser extent, Novartis's Exelon (rivastigmine) gain market share. However, sales of these drugs will decline during the second half of the study period because of the expiry of their patents. All agents in this class will lose patent protection by 2013."

With the commercial launch of the biomarker Pittsburgh Compound B and the availability of disease-modifying drugs during the second half of the forecast period, the study also finds that physicians will begin diagnosing Alzheimer's disease earlier in the progression of the illness.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Premium Increases Slowing to Single Digits in Maryland, Virginia, and the District of Columbia, According to New Research from HealthLeaders- InterStudy

View Now